Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2005-11-22
2005-11-22
Kunz, Gary (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S434000, C424S489000, C424S450000, C424S198100
Reexamination Certificate
active
06967017
ABSTRACT:
The present invention relates to optimized formulations of antiinflammatory steroids for nebulisation and a process for the preparation thereof. More particularly, the invention relates to formulations for monodose or multidose vials in the form of preservative-free stable solutions of a more acceptable osmolarity, which can effectively be nebulised with the nebulisers currently available on the market and are well-tolerated by patients.
REFERENCES:
patent: 3361306 (1968-01-01), Grim
patent: 3622053 (1971-11-01), Ryden
patent: 4185100 (1980-01-01), Rovee et al.
patent: 4499108 (1985-02-01), Sequeira et al.
patent: 4835145 (1989-05-01), MacDonald
patent: 5192528 (1993-03-01), Radhakrishnan et al.
patent: 5415853 (1995-05-01), Hettche et al.
patent: 5435297 (1995-07-01), Klein
patent: 5605674 (1997-02-01), Purewal et al.
patent: 5642728 (1997-07-01), Andersson et al.
patent: 5653961 (1997-08-01), McNally et al.
patent: 5676930 (1997-10-01), Jager
patent: 5683677 (1997-11-01), Purewal et al.
patent: 5695743 (1997-12-01), Purewal et al.
patent: 5891419 (1999-04-01), Cutie
patent: 5954047 (1999-09-01), Armer et al.
patent: 5955058 (1999-09-01), Jager et al.
patent: 6004537 (1999-12-01), Blondino et al.
patent: 6006745 (1999-12-01), Marecki et al.
patent: 6026808 (2000-02-01), Armer et al.
patent: 6045778 (2000-04-01), Jager et al.
patent: 6045784 (2000-04-01), Ruebusch et al.
patent: 6131566 (2000-10-01), Ashurst
patent: 6143277 (2000-11-01), Ashurst et al.
patent: 6149892 (2000-11-01), Britto
patent: 6150418 (2000-11-01), Hochrainer et al.
patent: 6241969 (2001-06-01), Saidi et al.
patent: 6253762 (2001-07-01), Britto
patent: 6290930 (2001-09-01), Blondino et al.
patent: 6315985 (2001-11-01), Wu et al.
patent: 6413496 (2002-07-01), Goodman et al.
patent: 6451285 (2002-09-01), Blondino et al.
patent: 6645466 (2003-11-01), Keller et al.
patent: 6713047 (2004-03-01), Lewis et al.
patent: 6716414 (2004-04-01), Lewis et al.
patent: 2001/0031244 (2001-10-01), Lewis et al.
patent: 2003/0066525 (2003-04-01), Lewis et al.
patent: 2003/0077230 (2003-04-01), Blondino et al.
patent: 2003/0089369 (2003-05-01), Lewis et al.
patent: 2003/0157028 (2003-08-01), Lewis et al.
patent: 2003/0190287 (2003-10-01), Lewis et al.
patent: 2003/0190289 (2003-10-01), Lewis et al.
patent: 2003/0206870 (2003-11-01), Lewis et al.
patent: 2004/0047809 (2004-03-01), Lewis et al.
patent: 2004/0062720 (2004-04-01), Lewis et al.
patent: 2004/0096399 (2004-05-01), Lewis et al.
patent: 2004/0184993 (2004-09-01), Lewis et al.
patent: 0 372 777 (1990-06-01), None
patent: 0 504 112 (1992-09-01), None
patent: 0 642 992 (1995-03-01), None
patent: 0 653 204 (1995-05-01), None
patent: 0 911 048 (1999-04-01), None
patent: 1 525 181 (1978-09-01), None
patent: 2 326 334 (1998-12-01), None
patent: WO 91/11173 (1991-08-01), None
patent: WO 92/11236 (1992-07-01), None
patent: WO 92/20391 (1992-11-01), None
patent: WO 93/05765 (1993-04-01), None
patent: WO 93/11743 (1993-06-01), None
patent: WO 93/11747 (1993-06-01), None
patent: WO 93/18746 (1993-09-01), None
patent: WO 94/13262 (1994-06-01), None
patent: WO 94/14490 (1994-07-01), None
patent: WO 94/21228 (1994-09-01), None
patent: WO 94/21229 (1994-09-01), None
patent: WO 95/17195 (1995-06-01), None
patent: WO 96/18384 (1996-06-01), None
patent: WO 96/19198 (1996-06-01), None
patent: 96 19969 (1996-07-01), None
patent: WO 96/19968 (1996-07-01), None
patent: WO 96/32099 (1996-10-01), None
patent: WO 96/32150 (1996-10-01), None
patent: WO 96/32151 (1996-10-01), None
patent: WO 96/32345 (1996-10-01), None
patent: WO 97/47286 (1997-12-01), None
patent: WO 98/01147 (1998-01-01), None
patent: WO 98/03533 (1998-01-01), None
patent: WO 98/05302 (1998-02-01), None
patent: WO 98/13031 (1998-04-01), None
patent: WO 98/24420 (1998-06-01), None
patent: WO 98/34595 (1998-08-01), None
patent: WO 98/34596 (1998-08-01), None
patent: WO 98/56349 (1998-12-01), None
patent: WO 99/12596 (1999-03-01), None
patent: WO 99/64014 (1999-12-01), None
patent: WO 99/65460 (1999-12-01), None
patent: WO 99/65464 (1999-12-01), None
patent: WO 00/06121 (2000-02-01), None
patent: WO 00/07567 (2000-02-01), None
patent: WO 00/23065 (2000-04-01), None
patent: WO 00/30608 (2000-06-01), None
patent: WO 00/35458 (2000-06-01), None
patent: WO 00/53157 (2000-09-01), None
patent: WO 00/78286 (2000-12-01), None
patent: WO 01/47493 (2001-07-01), None
Davis, S.S. Physico-chemical studies on aerosol solutions for drug delivery I. water-propylene glycol systems. International Journal of Pharmaceutics, 1 (1978) 71-83.
R.O. Williams III et al, “A study of an epoxy aerosol can lining exposed to hydrofluoroalkane propellants”,European Journal of Pharmaceutics and Biopharmaceutics, vol. 44, pp. 195-203, (1997).
ABPI Compendium of Data Sheets and Summaries of Product Characteristics, Datapharm Publications Limited, London, pp. 81-82, (1996-97).
Paul A. Sanders, Ph.D., “Homogeneous Systems and Their Properties”,Handbook of Aerosol Technology, Second Edition, Van Nostrand Reinhold Company, NY, p. 30, 1979.
G. Brambilla et al, “Modulation of Aerosol Clouds Produced by HFA Solution Inhalers”,Portable Inhalers, pp. 155-159, (Nov. 26 & 27, 1998).
B. Meakin, “Fine Particle Dose Control of Solution Based pMDIs”,Drug Delivery to the Lungs IX, The Aerosol Society, pp. 1-20, (Dec. 14 & 15, 1998).
Chet Leach, “Enhanced Drug Delivery Through Reformulating MDIs with HFA Propellants-Drug Deposition and Its Effect on Preclinical and Clinical Programs”,Respiratory Drug Delivery V, 1996, pp. 133-144.
L. Harrison et al, “Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects”,J. Pharm. Pharmacol., 1996, vol. 48, pp. 596-600.
P. Hoet et al, “Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons”,The Lancet, 1997, vol. 350, pp. 556-559.
J. Daly, Jr., “Properties and toxicology of CFC alternatives”,Aerosol Age, Feb. 1990, pp. 26-27, 40, 56 and 57.
D. Strobach, “Alternatives to CFCs” Part II,Aerosol Age, Jul. 1988, pp. 32-33, 42 and 43.
Tsi-Zong Tzou et al, “Drug Form Selection in Albuterol-Containing Metered-Dose Inhaler Formulations and Its Impact on Chemical and Physical Stability”,Journal of Pharmaceutical Sciences, 1997, vol. 86, No. 12, pp. 1352-1357.
M.J. Kontny et al, “Issues Surrounding MDI Formulation Development with Non-CFC Propellants”,Journal of Aerosol Medicine, 1991, vol. 4, No. 3, pp. 181-187.
I. P. Tansey, “Changing to CFC-Free Inhalers: The Technical and Clinical Challenges”,The Pharmaceutical Journal, 1997, vol. 259, pp. 896-898.
D. Tiwari et al, Compatibility Evaluation of Metered-Dose Inhaler Valve Elastomers with Tetrafluoroethane (P134a), a Non-CFC Propellant,Drug Development and Industrial Pharmacy, 1998, vol. 24, No. 4, pp. 345-352.
Handbook of Pharmaceutical Excipients, 3rd Ed., Kibbe Editor, pp. 7-9, 220-222, 234-235 and 560-561.
L. I. Harrison et al, “Pharmacokinetics and Dose Proportionality of Beclomethasone From Three Strengths of A CFC-Free Beclomethasone Dipropionate Metered-Dose Inhaler”,Biopharmaceutics&Drug Disposition, 1997, vol. 18, No. 7, pp. 635-643.
Brambilla Gaetano
Chiesi Paolo
Garzia Raffaella
Malvolti Chiara
Chiesi Farmaceutici S.p.A.
Haghighatian Mina
Kunz Gary
LandOfFree
Formulations of steroid solutions for inhalatory administration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations of steroid solutions for inhalatory administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations of steroid solutions for inhalatory administration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516829